Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
16.62
-0.04 (-0.24%)
At close: Nov 14, 2025, 4:00 PM EST
16.92
+0.30 (1.81%)
After-hours: Nov 14, 2025, 7:59 PM EST
Syndax Pharmaceuticals Revenue
Syndax Pharmaceuticals had revenue of $45.87M in the quarter ending September 30, 2025, with 266.97% growth. This brings the company's revenue in the last twelve months to $111.30M, up 595.65% year-over-year. In the year 2024, Syndax Pharmaceuticals had annual revenue of $23.68M.
Revenue (ttm)
$111.30M
Revenue Growth
+595.65%
P/S Ratio
12.92
Revenue / Employee
$412,237
Employees
270
Market Cap
1.44B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 23.68M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 139.71M | 138.19M | 9,109.56% |
| Dec 31, 2020 | 1.52M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SNDX News
- 5 days ago - Syndax Pharmaceuticals, Inc. (SNDX) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 10 days ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 10 days ago - Syndax Pharmaceuticals: Thesis Firing On All Cylinders, Sales Acceleration In 2026 - Seeking Alpha
- 12 days ago - Syndax Pharmaceuticals, Inc. (SNDX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 12 days ago - Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025 - GlobeNewsWire
- 12 days ago - Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025 - GlobeNewsWire
- 17 days ago - Syndax Announces Participation in November Investor Conferences - GlobeNewsWire